Tests for Suspected Parkinson's Disease in China: What Each Assessment Can Establish

Patients sometimes leave an initial appointment wondering why the neurologist spent time watching finger movements and walking rather than ordering a definitive scan. Others have undergone extensive imaging and still do not have a clear diagnosis. The value of a Parkinson's assessment lies in resolving a specific question. More tests do not necessarily produce greater certainty. Before organizing an evaluation in China, identify what the clinician needs to distinguish and how a result would affect treatment, timing, and cost.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The history establishes whether tremor, slowness, or gait change appeared first; which side was affected; and whether the change was gradual or abrupt. Examination may assess repeated finger movements, stiffness, rising from a chair, stride, turning, and postural control. Bradykinesia has specific clinical features. It is not established solely because someone takes longer to finish a task: pain, weakness, and mood can also slow activity.
Alpha-synuclein seed amplification assays seek a signal related to abnormal protein aggregation; they are not simply measurements of total protein concentration. The PPMI study demonstrated biological differences among participants and variation in positivity across genetic and clinical subgroups. A study's overall performance cannot be converted into a guarantee about an individual result. In particular, a negative assay should not be interpreted as proof that a person can never develop Parkinson's in the future. PPMI seed-amplification study
Some assessments produce a firm clinical conclusion, while others require observation over time. The clinician should explain the leading interpretation, what remains unresolved, which care can start now, and what changes should prompt earlier review. Constipation, reduced smell, or sleep behavior can be clues, but any one of them does not establish Parkinson's in a person without a compatible motor presentation. The MDS prodromal research criteria use a probability framework rather than turning a common symptom into a definite diagnosis. Updated MDS prodromal research criteria

Quick answer

Full guide

The clinical examination is part of the diagnostic work

The history establishes whether tremor, slowness, or gait change appeared first; which side was affected; and whether the change was gradual or abrupt. Examination may assess repeated finger movements, stiffness, rising from a chair, stride, turning, and postural control. Bradykinesia has specific clinical features. It is not established solely because someone takes longer to finish a task: pain, weakness, and mood can also slow activity.

The Movement Disorder Society criteria identify motor parkinsonism through bradykinesia with rest tremor or rigidity. Determining whether Parkinson's disease is the cause then requires supportive findings, warning features, and exclusion criteria. This explains why two patients described as having tremor can need different investigations and treatment. MDS clinical diagnostic criteria

Relatives can help by describing events rather than giving a general impression: when dressing became difficult, whether coughing occurs with drinks, or what unusual movements happen during sleep. If the patient and family describe different experiences, preserve both accounts. The clinician can then decide which situations need further assessment, particularly when they cannot be reproduced during a short appointment. Existing videos can be useful, but a recording cannot reproduce all parts of a neurological examination.

Review medicines before assuming another scan is the answer

Certain psychiatric, anti-nausea, and other medicines can affect movement. A complete list should include prescription drugs, nonprescription products, and supplements, with names, amounts, and starting dates. Labels such as “stomach medicine” are too imprecise. Symptoms beginning after a new prescription or a dose increase are worth reporting, but this is not a reason to independently stop treatment for another illness.

Diagnosis requires integration by a clinician trained to recognize these patterns. The MDS diagnostic position statement emphasizes that supportive findings cannot establish Parkinson's on their own. Routine blood tests and an EEG are not general confirmatory tests for Parkinson's disease. Blood work can nevertheless investigate another suspected cause, a related illness, or readiness for treatment. A normal laboratory report does not negate an observed movement problem. MDS position on diagnosis

A normal structural MRI does not settle the question

Conventional MRI mainly examines structure. It cannot, by itself, confirm or exclude typical Parkinson's disease. It may help identify other explanations for symptoms, especially when the history or examination is unusual. Atrophy, white-matter changes, and old lesions also need clinical interpretation; an abnormal phrase in the report is not automatically the explanation for the patient's movement difficulties.

NICE distinguishes using structural MRI to diagnose Parkinson's from using it to help assess other parkinsonian syndromes. Send both the report and the original image data before a visit to China so the receiving doctor can decide whether the previous study answers the relevant question. A photograph of the written conclusion may be insufficient for review. Ask why repetition is proposed if a recent adequate study is available. NICE diagnostic recommendations

Dopamine transporter imaging has a defined diagnostic role

Specialists may consider dopaminergic functional imaging when a particular tremor or parkinsonian presentation remains uncertain. The US DATSCAN label describes SPECT visualization of striatal dopamine transporters as an adjunct to other diagnostic evaluation. An abnormal scan is not designed to distinguish Parkinson's disease from multiple system atrophy or progressive supranuclear palsy. Interpreting reduced uptake as a unique disease name overstates what this test establishes. FDA DATSCAN label, 2026

Some medicines can affect image interpretation, so the imaging service should review the complete medication list and decide whether any change is appropriate and safe. Do not follow an online drug-withdrawal schedule without that review. Discuss pregnancy possibility, breastfeeding, allergies, and relevant medical conditions as part of preparation. The tracer, equipment, authorized use, and scheduling available in China may differ from a foreign product description. Establish the exact local test rather than assuming an overseas brand name refers to the service being offered.

What China's 2026 PET/MRI guideline adds

Integrated PET/MRI combines functional and structural information and may contribute to selected uncertain diagnoses or differentiation of atypical parkinsonian syndromes. The 2026 Chinese guideline addresses suitable clinical scenarios, tracers, interpretation, and the realities of local equipment and tracer access. It is guidance for a particular imaging technique, not a requirement that every newly assessed patient undergo PET/MRI. Chinese integrated PET/MRI clinical guideline

Ask which competing diagnoses remain, what different results would change, and whether existing information already resolves the decision. “The machine is more advanced” does not answer those questions. Recommendations can also vary by publication period and jurisdiction. Neither an older overseas restriction nor a description of a new Chinese imaging service should be presented as a rule for every patient. The clinical problem should determine whether the additional examination has useful value.

Cerebrospinal-fluid seed amplification is a distinct laboratory method

Alpha-synuclein seed amplification assays seek a signal related to abnormal protein aggregation; they are not simply measurements of total protein concentration. The PPMI study demonstrated biological differences among participants and variation in positivity across genetic and clinical subgroups. A study's overall performance cannot be converted into a guarantee about an individual result. In particular, a negative assay should not be interpreted as proof that a person can never develop Parkinson's in the future. PPMI seed-amplification study

Before cerebrospinal fluid is collected, ask whether the purpose is clinical differentiation, research classification, or screening for a trial. Clarify who will explain the result and whether it would alter current management. Lumbar puncture has its own preparation and aftercare requirements; the team should review anticoagulants and relevant medical history. If traveling for assessment, leave room for the procedure and its follow-up rather than scheduling invasive testing immediately before a demanding journey. The ability to obtain a specimen is not, by itself, a reason to request the test.

A positive skin biopsy still needs clinical interpretation

A 2024 JAMA study detected phosphorylated alpha-synuclein in skin biopsies across several synucleinopathies, not only Parkinson's disease. A positive finding can therefore support a pathological process without identifying a unique clinical syndrome. The study involved professionally classified participants; an unselected clinic population and a different laboratory workflow may not reproduce the same performance. These limits should accompany the result rather than disappear behind a single accuracy figure. Original skin-biopsy investigation

Confirm the sampling sites, laboratory method, report content, and arrangements for an inconclusive or unsuccessful sample. Services using the phrase “alpha-synuclein testing” may examine different specimens in different ways. Comparing only the price or the word “positive” can therefore be misleading. If a previous result exists, first ask why it does not resolve the current question. A second test with a similar name may or may not provide independent useful information.

Genetic testing begins with a purpose and counseling

Young onset, a relevant family history, or a particular research opportunity can make genetic counseling especially useful. Patients without those features may also wish to discuss testing, but should understand the expected information. A disease-causing variant, a risk variant, and a variant of uncertain significance have different meanings. Some variants do not result in disease in every carrier. Because one person's findings may affect relatives' choices, explanation before testing matters as much as interpretation afterward. Expert review of Parkinson's genetic testing

Ask what genes and variant types are covered, whether clinical confirmation is required, and whether counseling is included. Consumer testing or a research screen is not automatically sufficient for a treatment decision. For testing in China followed by counseling at home, retain the full laboratory report, variant notation, and date of interpretation. A translated summary that says only “genetic Parkinson's” may prevent the next clinician from checking what was actually found. Discuss how the result will be stored and shared before involving unaffected relatives.

Rating scales describe the condition rather than identify its cause

The MDS-UPDRS assesses nonmotor experiences of daily living, motor experiences of daily living, the motor examination, and motor complications. It helps describe problems and follow response, but there is no simple total-score threshold that diagnoses Parkinson's as if it were an abnormal blood concentration. Medication state, timing, and functional context matter. A score obtained just after a beneficial dose cannot be directly compared with a score during wearing off without accounting for those conditions. Original MDS-UPDRS validation

Cognitive, mood, sleep, standing-blood-pressure, or swallowing assessments should also answer a clinical or treatment question. Some establish safety needs; others contribute to suitability for a procedure or provide a baseline for follow-up. In a consultation across languages, arrange explanations the patient understands and an appropriate-language assessment. Difficulty understanding the examiner must not be mistaken for cognitive impairment. The goal is a faithful account of function, not completion of the largest number of forms.

Finish with a plan for the remaining uncertainty

Some assessments produce a firm clinical conclusion, while others require observation over time. The clinician should explain the leading interpretation, what remains unresolved, which care can start now, and what changes should prompt earlier review. Constipation, reduced smell, or sleep behavior can be clues, but any one of them does not establish Parkinson's in a person without a compatible motor presentation. The MDS prodromal research criteria use a probability framework rather than turning a common symptom into a definite diagnosis. Updated MDS prodromal research criteria

An evaluation trip should include an appointment to interpret results, not end immediately after the final scan. Request an itemized renminbi estimate covering consultation, imaging, laboratory tests, procedures, translation if offered, and follow-up, with expected reporting times. If results remain uncertain, identify who will monitor the patient and whether suggested repeat assessments can occur locally. Testing has served its purpose when the patient understands the next clinical step, rather than merely leaving with a stack of documents.

Evidence checked: September 9, 2026. Test selection and interpretation depend on the individual's history, examination, and the receiving hospital's capabilities.